Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition-Reference-Cited by-同舟云学术

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition

Published:2018-06 Issue:6 Volume:109 Page:2074-2079
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Yamazaki Kentaro¹^ORCID,Taniguchi Hiroya²,Yoshino Takayuki³,Akagi Kiwamu⁴,Ishida Hideyuki⁵,Ebi Hiromichi⁶,Nakatani Kaname⁷,Muro Kei²,Yatabe Yasushi⁸,Yamaguchi Kensei⁹,Tsuchihara Katsuya¹⁰

Affiliation:

1. Division of Gastrointestinal Oncology; Shizuoka Cancer Center; Shizuoka Japan

2. Department of Clinical Oncology; Aichi Cancer Center Hospital; Aichi Japan

3. Department of Gastrointestinal Oncology; National Cancer Center Hospital East; Kashiwa Japan

4. Division of Molecular Diagnosis and Cancer Prevention; Saitama Cancer Center; Saitama Japan

5. Department of Digestive Tract and General Surgery; Saitama Medical Center; Saitama Medical University; Saitama Japan

6. Division of Medical Oncology; Cancer Research Institute; Kanazawa University; Ishikawa Japan

7. Central Laboratory; Mie University Hospital; Mie Japan

8. Department of Pathology and Molecular Diagnostics; Aichi Cancer Center Hospital; Aichi Japan

9. Department of Gastroenterological Chemotherapy; Cancer Institute Hospital of Japanese Foundation for Cancer Research; Tokyo Japan

10. Division of Translational Research; Exploratory Oncology Research and Clinical Trial Center; National Cancer Center; Chiba Japan

Funder

Japanese Society of Medical Oncology

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13617/fullpdf

Reference8 articles.

1. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients;Taniguchi;Cancer Sci,2015

2. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer;Watanabe;Int J Clin Oncol,2018

3. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann Oncol,2018

4. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

5. Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer;Corcoran;Cancer Discov,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix;Frontiers in Pharmacology;2022-11-17

2. Risk assessment and genetic counseling for Lynch syndrome – Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer;Journal of Genetic Counseling;2022-01-09

3. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories;Human Pathology;2021-08

4. Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, 4th edition;Cancer Science;2020-09-04

5. Evaluation of KRAS, NRAS and BRAF mutational status and microsatellite instability in early colorectal carcinomas invading the submucosa (pT1): towards an in-house molecular prognostication for pathologists?;Journal of Clinical Pathology;2020-04-09